Mechanism for increase in expression of cerebral diazepam binding inhibitor mRNA by nicotine: involvement of L-type voltage-dependent calcium channels

Brain Res Mol Brain Res. 2000 Sep 15;80(2):132-41. doi: 10.1016/s0169-328x(00)00119-4.

Abstract

We investigated the mechanisms underlying the increase in diazepam binding inhibitor (DBI) and its mRNA expression induced by nicotine (0.1 microM) exposure for 24 h using mouse cerebral cortical neurons in primary culture. Nicotine-induced (0.1 microM) increases in DBI mRNA expression were abolished by hexamethonium, a nicotinic acetylcholine (nACh) receptor antagonist. Agents that stabilize the neuronal membrane, including tetrodotoxin (TTX), procainamide (a Na(+) channel inhibitor), and local anesthetics (dibucaine and lidocaine), dose-dependently inhibited the increased expression of DBI mRNA by nicotine. The nicotine-induced increase in DBI mRNA expression was inhibited by L-type voltage-dependent Ca(2+) channel (VDCC) inhibitors such as verapamil, calmodulin antagonist (W-7), and Ca(2+)/calmodulin-dependent protein kinase II (CAM II kinase) inhibitor (KN-62), whereas P/Q- and N-type VDCC inhibitors showed no effects. In addition, nicotine exposure for 24 h induced [3H]nicotine binding to the particulate fractions of the neurons with an increased B(max) value and no changes in K(d). Under these conditions, the 30 mM KCl- and nicotine-induced 45Ca(2+) influx into the nicotine-treated neurons was significantly higher than those into non-treated neurons. These results suggest that the nicotine-stimulated increase in DBI mRNA expression is mediated by CAM II kinase activation resulting from the increase in intracellular Ca(2+) through L-type VDCCs subsequent to the neuronal membrane depolarization associated with nACh receptor activation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / analogs & derivatives*
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / pharmacology
  • Anesthetics, Local / pharmacology
  • Animals
  • Binding, Competitive / physiology
  • Calcium Channel Blockers / pharmacology
  • Calcium Channels, L-Type / metabolism*
  • Calcium Radioisotopes / pharmacokinetics
  • Calcium-Calmodulin-Dependent Protein Kinases / metabolism
  • Carrier Proteins / genetics*
  • Cells, Cultured
  • Cerebral Cortex / cytology
  • Diazepam Binding Inhibitor
  • Dibucaine / pharmacology
  • Enzyme Inhibitors / pharmacology
  • Gene Expression / drug effects
  • Gene Expression / physiology
  • Hexamethonium / pharmacology
  • Lidocaine / pharmacology
  • Membrane Potentials / drug effects
  • Membrane Potentials / physiology
  • Mice
  • Neurons / chemistry
  • Neurons / cytology
  • Neurons / enzymology*
  • Nicotine / metabolism
  • Nicotine / pharmacology*
  • Nicotinic Agonists / metabolism
  • Nicotinic Agonists / pharmacology*
  • Nicotinic Antagonists / pharmacology
  • Platelet Aggregation Inhibitors / pharmacology
  • Procainamide / pharmacology
  • RNA, Messenger / metabolism
  • Sulfonamides / pharmacology
  • Tetrodotoxin / pharmacology
  • Tritium
  • omega-Agatoxin IVA / pharmacology
  • omega-Conotoxin GVIA / pharmacology

Substances

  • Anesthetics, Local
  • Calcium Channel Blockers
  • Calcium Channels, L-Type
  • Calcium Radioisotopes
  • Carrier Proteins
  • Diazepam Binding Inhibitor
  • Enzyme Inhibitors
  • Nicotinic Agonists
  • Nicotinic Antagonists
  • Platelet Aggregation Inhibitors
  • RNA, Messenger
  • Sulfonamides
  • omega-Agatoxin IVA
  • Tritium
  • Hexamethonium
  • Tetrodotoxin
  • KN 62
  • W 7
  • Nicotine
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
  • omega-Conotoxin GVIA
  • Lidocaine
  • Calcium-Calmodulin-Dependent Protein Kinases
  • Procainamide
  • Dibucaine